Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NGM

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

NGM Biopharmaceuticals logo

About NGM Biopharmaceuticals Stock (NASDAQ:NGM)

Advanced Chart

Key Stats

Today's Range
$1.54
$1.54
50-Day Range
$1.52
$1.63
52-Week Range
$0.60
$4.69
Volume
N/A
Average Volume
1.47 million shs
Market Capitalization
$128.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NGM Stock News Headlines

The stealth altcoin the financial world is underestimating
This DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening RIGHT NOW—this project is poised to see massive moves.... The smart money is already positioning.tc pixel
See More Headlines

NGM Stock Analysis - Frequently Asked Questions

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) announced its earnings results on Thursday, November, 4th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.03. The business earned $18.58 million during the quarter, compared to analyst estimates of $18.90 million. NGM Biopharmaceuticals had a negative net margin of 3,223.34% and a negative trailing twelve-month return on equity of 77.85%.

NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that NGM Biopharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and PayPal (PYPL).

Company Calendar

Last Earnings
11/04/2021
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NGM
CIK
1426332
Fax
N/A
Employees
138
Year Founded
1998

Profitability

EPS (Trailing Twelve Months)
($1.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$142.38 million
Net Margins
-3,223.34%
Pretax Margin
-3,223.34%
Return on Equity
-77.85%
Return on Assets
-67.76%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.79
Quick Ratio
7.79

Sales & Book Value

Annual Sales
$4.42 million
Price / Sales
29.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.80 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
83,462,000
Free Float
53,499,000
Market Cap
$128.53 million
Optionable
Optionable
Beta
1.27

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:NGM) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners